Risk Factors for Late-onset or Progressive Hearing Loss:

Newborn Screening is just the beginning, not the end

February, 2017 Susan Wiley, MD susan.wiley@cchmc.org Division of Developmental and Behavioral Pediatrics

> Cincinnati Children's changing the outcome together

Conflict of Interest

• I have no conflicts of interest to report



Learning Objectives

- Identify risk factors for late onset or progressive hearing loss
- With the goal of having teams consider this information when developing strategies to identify and track children with risk factors within primary care



2013 National CDC EHDI data

Total Births	3,904,742	%		
Number screened	3,478,986	97		
Not passing	61,419	1.6		
Diagnosed	31,318	58.7		
Normal hearing	26,022	48.8		
Hearing Loss	5,296	9.9		
Rate of hearing loss	1.5/1000			
Referred to El	4,817	87.4		
Risk Factors	NO CONSISTENT POPULATION DATA			

http://www.cdc.gov/ncbddd/hearingloss/2013-data/2013_ehdi_hsfs_summary___



Risk Factors for SNHL Martinez-Cruz et al Arch Med Res 2008

Risk Factor	SNHL(146) Yes/No	Control (272) Yes/No	OR	95% CI		р
Prenatal steroids	20/126	77/195	0.377	0.194	0.732	<0.001
Surfactant	27/119	110/162	0.331	0.176	0.579	<0.001
Asphyxia	41/105	67/205	1.166	0.738	1.841	0.55
Exchange	40/106	12/260	8.176	4.128	16.195	<0.000
Meningitis	15/131	7/265	4.368	1.738	10.976	<0.002
Amikacin	134/12	229/43	2.097	1.068	4.116	<0.033
Furosemide	114/32	131/141	3.834	2.424	6.066	<0.000
Persistent fetal circulation	12/134	14/258	1.650	0.742	3.668	0.288
IVH	71/75	32/240	7.100	4.344	11.605	<0.000
BPD	75/71	50/222	4.690	3.001	7.331	<0.000
					changing	the outcome together

Risk Indicators for permanent congenital, delayed onset or progressive hearing loss *noted at birth*

- Family history*
 - of permanent childhood hearing loss

- NICU stay > 5 days or any of following (regardless of length of stay):
 - ECMO assisted ventilation*
 - Ototoxic medications (such as gentamycin, tobramycin)
 - Loop diuretics (furosemide, Lasix)
 - Hyperbilirubinemia requiring exchange transfusion



Risk Indicators for permanent congenital, delayed onset or progressive hearing loss *noted at birth*

- In Utero infections
 - CMV*, herpes, rubella, syphilis, toxoplasmosis, Zika
- Craniofacial anomalies
 - especially those involving the pinna, ear canal, ear tags, ear pits, and temporal bone anomalies
 - Children with cleft lip and palate are at higher risk for conductive hearing loss requiring monitoring and aggressive treatment of middle ear status

JCIH, 2007



* = greater risk for **delayed** onset HL

Risk Indicators for permanent congenital, delayed onset or progressive hearing loss

- Physical findings associated with a syndrome known to include permanent HL (e.g. white forelock)
- Syndromes* involving hearing loss (such as) Down Syndrome, Neurofibromatosis, Osteopetrosis, Usher Syndrome, Waardenburg Syndrome Alport Syndrome Pendred Syndrome Jervell & Lange-Nielson

* = greater risk for **delayed** onset HL



Risk Indicators for permanent congenital, delayed onset or progressive hearing *post-natal*

- Neurodegenerative disorders
 - Hunter syndrome
 - Sensory motor neuropathies (Frieidrich ataxia, Charcot-Marie-Tooth)
- Culture positive postnatal infections associated with HL*
 - Herpes, varicella, meningitis
- Head trauma (basal skull, temporal bone)*
- Chemotherapy*



Current JCIH monitoring interval statements

- The timing and number of hearing reevaluations for children with risk factors should be **customized and individualized** depending on the **relative likelihood** of a subsequent delayed-onset hearing loss.
- Infants who pass the neonatal screening but have a risk factor should have at least 1 diagnostic audiology assessment by 24 to 30 months of age.



Current JCIH monitoring interval statements

- Early and more frequent assessment may be indicated for children with cytomegalovirus (<u>CMV</u>) infection, <u>syndromes</u> associated with progressive hearing loss, <u>neurodegenerative disorders</u>, <u>trauma</u>, or culture positive <u>postnatal infections</u> associated with sensorineural hearing loss; for children who have received extracorporeal membrane oxygenation (<u>ECMO</u>) or chemotherapy;
- And when there is <u>caregiver concern</u> or a <u>family history</u> of hearing loss.



Follow-up of Infant with Perinatal Risk Factor for Hearing Loss

Risk Factor	JCIH 2007	JCIH 2015	Monitoring; Parent concerns always prompt evaluation
Caregiver concern regarding hearing, speech, language delays	Immediate referral	Immediate referral	According to findings & concerns
Family History of hearing loss	24-30 m	By 7-9 m	Based on etiology
NICU care> 5 days, & regardless of LOS:	24-30 m	By 7-9 m	According to findings & concerns
ECMO	24-30 m	≤ 3 m	Every 12 m to school
hyperbilirubinemia with exchange transfusion.	24-30 m	By 7-9 m	
assisted ventilation	24-30 m	>5d By 7-9 m	According to findings &
ototoxic medications	24-30 m	>5d By 7-9 m	concerns
loop diuretics (Lasix),	24-30 m	>5d By 7-9 m	
Asphyxia or HIE	NA	By 7-9 m	

in the outcome together

Follow-up of Infant with Perinatal Risk Factor for Hearing Loss

Risk Factor	JCIH 2007	JCIH 2015	Monitoring; Parent concerns always prompt evaluation
In-utero Torch infections	24-30m	7-9m	As per concerns of hearing & speech
CMV infection	24-30m	By 3m	Q 12 m to school age



Follow-up of Infant with Perinatal Risk Factor for Hearing Loss

Risk Factor	JCIH 2007	JCIH 2015	Monitoring; Parent concerns always prompt evaluation
Craniofacial anomalies, especially those involving the pinna, ear canal, ear tags, ear pits, and temporal bone anomalies	24-30	7-9m	As per concerns of on- going surveillance
Physical findings associated with a syndrome known to include permanent HL	24-30	7-9m	As per concerns of on- going surveillance
Syndromes associated with progressive HL such as NF, osteopetrosis, Usher's syndrome	24-30	7-9m	According to natural history of syndrome or concerns
Neurodegenerative disorders*, such as Hunter syndrome	24-30	7-9m	As per concerns of on- going surveillance



Follow-up of Infant with Risk Factor(Perinatal or Postnatal) for Hearing Loss

Risk Factor	JCIH 2007	JCIH 2015	Monitoring; Parent concerns always prompt evaluation
Head Trauma	Follow-up	≤ 3months	Surveillance/concerns
Chemo therapy*	Not	≤ 3months	Surveillance/concerns
Culture-positive infections associated with sensorineural hearing loss*, including confirmed bacterial and viral (especially herpes viruses and varicella) meningitis or encephalitis	specifically stated	≤ 3months	Q 12 m or per concerns
Caregiver concern* regarding hearing, speech, language developmental delay and or developmental regression	immediate	immediate	immediate



Bob's list of strategies

- Discuss results of the newborn hearing screening with parents
- Identify factors that place a baby at risk of hearing loss in the future
- Develop, discuss, and document an individualized plan for following babies who have risk factors. At a minimum, this should include a follow-up audiological evaluation within the first year of life. Some risk factors, however, may demand an earlier evaluation



Bob's list of strategies

- Modify your electronic medical record or paper chart as a way to prompt a discussion of risk factors and give a place to document that it occurred
- **Develop a diagnostic code** for those patients identified "at risk" for hearing loss
 - This will allow a way to track those <u>patients who require</u> <u>follow up</u>
 - The <u>responsibility for tracking</u> should also be <u>assigned</u> to a single office staff person
- Act on parental concern about hearing loss since it is a risk factor that should result in a prompt referral for evaluation. Never ignore a parental concern or dissuade a family from receiving an evaluation because the baby passed the newborn screen and therefore "could not have a problem with their hearing"



- Maintain a high level of suspicion for late-onset hearing loss
 - Remember, a passed newborn hearing screen does not protect an individual from hearing loss forever
 - Send for diagnostic evaluation at any point families have concerns or there is speech/language delay
- It is helpful to document risk factors for delayed onset or progressive hearing loss and monitor hearing and speech/language milestones in children experiencing these risk factors

